Earkart Limited
Earkart Manufacture and distribute modern hearing aids and related accessories at affordable price across India. Along with our own manufactured hearing aid, we also trade in hearing aid, parts and accessories of other brands manufactured in India and abroad.(Source : 202509 Prospectus Page No: 20)
- Market Cap ₹ 165 Cr.
- Current Price ₹ 120
- High / Low ₹ 266 / 114
- Stock P/E 30.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 45.1 %
- ROE 41.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Cons
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 5.66 | 28.92 | 31.75 | 43.11 | |
| 5.52 | 27.29 | 28.17 | 33.32 | |
| Operating Profit | 0.14 | 1.63 | 3.58 | 9.79 |
| OPM % | 2.47% | 5.64% | 11.28% | 22.71% |
| 0.04 | 0.05 | 0.21 | 0.09 | |
| Interest | 0.01 | 0.08 | 0.36 | 0.44 |
| Depreciation | 0.06 | 0.15 | 0.19 | 0.42 |
| Profit before tax | 0.11 | 1.45 | 3.24 | 9.02 |
| Tax % | 0.00% | 9.66% | 5.86% | 23.61% |
| 0.11 | 1.31 | 3.06 | 6.88 | |
| EPS in Rs | 22.00 | 262.00 | 612.00 | 6.59 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 97% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 297% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 42% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 10.44 | 13.75 |
| Reserves | 4.72 | 6.49 | 12.97 | 9.48 | 52.31 |
| 0.27 | 1.23 | 4.02 | 4.96 | 5.62 | |
| 0.91 | 6.96 | 2.21 | 5.41 | 6.50 | |
| Total Liabilities | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
| 0.22 | 0.25 | 1.06 | 1.17 | 1.61 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.46 | 0.10 | 0.19 | 0.83 | 0.83 |
| 4.27 | 14.38 | 18.00 | 28.29 | 75.74 | |
| Total Assets | 5.95 | 14.73 | 19.25 | 30.29 | 78.18 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -2.83 | -0.30 | -1.00 | 0.71 | |
| -1.78 | 0.40 | -1.29 | -1.32 | |
| 4.68 | 0.41 | 3.08 | -0.41 | |
| Net Cash Flow | 0.07 | 0.51 | 0.80 | -1.01 |
| Free Cash Flow | -3.11 | -0.48 | -1.99 | 0.18 |
| CFO/OP | -2,007% | -17% | -22% | 30% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 104.47 | 59.32 | 72.89 | 157.23 |
| Inventory Days | 138.26 | 100.90 | 113.12 | 95.52 |
| Days Payable | 92.17 | 107.33 | 19.28 | 44.04 |
| Cash Conversion Cycle | 150.56 | 52.89 | 166.73 | 208.70 |
| Working Capital Days | 192.17 | 60.83 | 108.06 | 139.02 |
| ROCE % | 23.89% | 29.02% | 45.13% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|
| Revenue Mix - Government Sector % |
|
|||
| Large Government Orders (ALIMCO/GeM) Units |
||||
| Revenue Mix - Private Sector % |
||||
| Shop-in-Shop (SIS) Clinics Number |
||||
| Annual Production Capacity (Hearing Aids) Units |
||||
| Dealer Partners Number |
||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Apr - Newspaper Advertisement of the Postal Ballot Notice of the Earkart Limited(''The Company'')
-
Shareholder Meeting/ Postal Ballot- Notice Of Postal Ballot
2 Apr - Postal ballot seeks approval to reallocate unutilized IPO proceeds into working capital, pharma, and acquisitions.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Mar - Appointed M/s. Arvind Aggarwal & Associates as internal auditor for FY2025-26 on March 30, 2026.
- Closure of Trading Window 30 Mar
-
Board Meeting Intimation for Prior Intimation Of The Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015, As Amended ('SEBI LODR Regulations')- Board Meeting To Be Held On 30Th March 2026
20 Mar - Board meeting on 30 Mar 2026 to consider varying IPO proceeds utilization and extending utilization timeline.
Annual reports
No data available.
Concalls
-
Jan 2026TranscriptAI SummaryPPTREC
-
Dec 2025Transcript PPT
Business Profile[1]
Earkart manufactures and distributes modern hearing aids (BTE & RIC) and accessories, trades third-party hearing aids and parts, and also supplies mobility aids (foldable walkers) and educational/therapy kits (MSIED and TLM) for children with disabilities.